Aim: The purpose of this study was to determine the effect of Bleomycin (BLM) sclerotherapy intralesional injection in intraosseous hemangioma of the mandible (IHMs). Patients and methods: This study was conducted on 7 child patients 5 females and 2 males, their ages ranged from 9 to 12 years of with a mean of 10. 4 years, the patients were collected from both the Oral & Maxillofacial Surgery department Faculty of Dentistry, Tanta. Suez Canal University and Zagazig University Hospital from the period of JUN 2017 to AUGUST 2021. Bleomycin (BLM) agent was evaluated according to its clinical effect on the lesions. And its radiographic effect at the follow-up period by CT scan. Results: Five cases showed the occurrence of complete response, and two Cases showed the occurrence of marked improvement after, intralesional injection of BLM. Clinically no pain had been detected at the end of the follow-up period, no ulceration had been detected at the site of injection, no bleeding had been detected from the lesion whether spontaneously nor with slight touch in all cases. Orthopantograms and CT Scan and showed an increase in radiopacity of the lesion and a decrease of the lesion cavity size in all cases both after 3 and 6 months from BLM injection. Conclusions: Bleomycin is a safe and cost-effective drug, as a sclerosing agent in the management of child intraosseous hemangiomas.